_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expands bioprocessing footprint across Asia
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated
